ADDYI Pregnancy Registry Study

The ADDYI Pregnancy Registry Study was developed in collaboration with the FDA and Sprout Pharmaceuticals, Inc. This observational study seeks to evaluate pregnancy-related health outcomes of a cohort of women who were exposed to at least one dose of ADDYI at any time point during their pregnancy, compared to a cohort of pregnant women who were never exposed to ADDYI or who stopped taking ADDYI at least one month prior to becoming pregnant.

The Study also seeks to evaluate infant health outcomes including major congenital anomalies, postnatal growth, and development through one year of age in each cohort.

To enroll in the study or request additional information:

Visit AddyiPregnancy.com

Call the Pregnancy Coordinating Center at 855-265-6954

Email the Pregnancy Coordinating Center at ADDYIPregnancy@ubc.com